IMMUNOVANT INC IMVT 深 滬
等待開盤 10-28 09:30:00 美东时间
21.43
+2.490
+13.15%
華盛通- 最 高21.82
- 今 開19.21
- 成交量 246.47万股
- 最 低 19.21
- 昨 收 18.94
- 總市值 36.65亿
- 52周最高 32.10
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 12.72
- 委 比 -73.36%
- 總股本 1.71亿
- 歷史最高 53.75
- 量 比 1.34
- 振 幅 13.78%
- 歷史最低 3.145
- 每 手 1
- 風險率 4.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Immunovant announced it will report its Q2 2025 financial results and provide a business update on November 10, 2025, at 8:00 a.m. ET. Interested parties can register for the Roivant conference call via the provided link. The presentation and webcast will also be accessible on Immunovant’s website, with an archived version available post-call. Immunovant is a clinical-stage immunology company focused on developing innovative therapies for autoimm...
10-27 20:10
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Truist Securities Initiates Coverage On Immunovant with Hold Rating, Announces Price Target of $16
Truist Securities analyst Danielle Brill initiates coverage on Immunovant (NASDAQ:IMVT) with a Hold rating and announces Price Target of $16.
10-14 21:11
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
JP Morgan Maintains Overweight on Immunovant, Lowers Price Target to $33
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $37 to $33.
09-30 20:29
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.
09-18 00:13
Immunovant Reports Durability And Treatment-Free 6-Month Remission Data; Unveils ~80% Response Rate In Off-Treatment Graves' Disease Study
First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal
09-04 01:00
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant's batoclimab shows promising results for Graves' disease, with 80% of patients achieving normal thyroid function and 50% remaining off anti-thyroid drugs after six months. Two registrational trials for IMVT-1402 are ongoing, with results expected in 2027. Immunovant will discuss the updates during an investor call on September 3, 2025. These findings may offer a potential disease-modifying therapy for previously uncontrolled patients, ...
09-03 16:57
Leaders Come Together to Advance the Industry at Veeva Summit
Alnylam Pharmaceuticals, BeOne Medicines, Intercept Pharmaceuticals, Merck, Pfizer, and Sanofi among biopharmas sharing strategies that set future direction Veeva to showcase innovations, in...
08-21 19:03
JP Morgan Maintains Overweight on Immunovant, Lowers Price Target to $37
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $40 to $37.
08-12 23:44
